LoginSignup
Imagen de perfil
Aktien Stammtisch
@Aktien_Stammtisch
2Lun·

$ABBV (-1,77 %)
AbbVie Reports Phase 2 EMPOWER Trials For Emraclidine In Schizophrenia Miss Primary Endpoint; Treatment Well-Tolerated, Further Data Analysis Underway


$BMY (-1,04 %) Bristol-Myers Squibb seems to benefits from this +13%

10
11 Comentarios
Sebastian B.@Baisse-Jumper
2Lun
Should it go down another 10%-15% at $ABBV: 🛒🛒🛒🛒
•
9
•
Imagen de perfil
Iwas M.@SSIT
2Lun
If AbbVie goes down even further, I might spontaneously get in today ^^
•
3
•
Imagen de perfil
Memo0606@Memo0606
2Lun
@SSIT swiss
think it's good for shopping
•
1
•
Imagen de perfil
Iwas M.@SSIT
2Lun
@Memo0606 I was a fool and opted for Johnson & Johnson when both values were around 140€ 😭 This value has simply burned itself into me.
•
1
•
Imagen de perfil
Memo0606@Memo0606
2Lun
@SSIT well $JNJ i think it's not bad there are just more dividends
I am also invested
•
2
•
Sebastian B.@Baisse-Jumper
2Lun
@Memo0606 Not even yet. $ABBV already has a higher dividend yield and growth is also better. Nevertheless, $JNJ is already a good share.
•
2
•
Imagen de perfil
Thomas@WolfofNersingen
2Lun
Am in
•
2
•
Imagen de perfil
Vertriebsliebhaber@Vertriebsliebhaber
2Lun
Hach, 30% at $BMY in 6 months. I can live with that 🥳😎
•
2
•
Imagen de perfil
Saschko@WarrenamBuffet
2Lun
stupid :(
••
Imagen de perfil
Stefan@Slucks87
2Lun
Gut :)
••
Proolix@Proolix
2Lun
Hm... in my overview AbbVie is shown with minus 20%. If I go to the share with minus 12% ... 🤷‍♀️ is this a known error or what is the reason for this? 🤷‍♀️
••
Únase a la conversación
InscríbaseInicio de sesión